Follow
Suzette Delaloge
Suzette Delaloge
Verified email at gustaveroussy.fr
Title
Cited by
Cited by
Year
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ...
Nature medicine 13 (9), 1050-1059, 2007
33282007
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
M Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, ...
New England Journal of Medicine 377 (6), 523-533, 2017
29102017
70-gene signature as an aid to treatment decisions in early-stage breast cancer
F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ...
New England Journal of Medicine 375 (8), 717-729, 2016
18412016
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ...
Nature medicine 20 (11), 1301-1309, 2014
10092014
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
L Apetoh, F Ghiringhelli, A Tesniere, A Criollo, C Ortiz, R Lidereau, ...
Immunological reviews 220 (1), 47-59, 2007
6852007
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2 …
ME Robson, N Tung, P Conte, SA Im, E Senkus, B Xu, N Masuda, ...
Annals of Oncology 30 (4), 558-566, 2019
6452019
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
6352017
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 …
A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ...
The Lancet Oncology 17 (3), 367-377, 2016
6262016
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
MV Dieci, C Criscitiello, A Goubar, G Viale, P Conte, V Guarneri, G Ficarra, ...
Annals of oncology 25 (3), 611-618, 2014
5362014
Breast cancer with synchronous metastases: trends in survival during a 14-year period
F Andre, K Slimane, T Bachelot, A Dunant, M Namer, A Barrelier, ...
Journal of Clinical Oncology 22 (16), 3302-3308, 2004
5222004
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ...
Annals of oncology 32 (10), 1216-1235, 2021
4682021
21-gene assay to inform chemotherapy benefit in node-positive breast cancer
K Kalinsky, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, ...
New England Journal of Medicine 385 (25), 2336-2347, 2021
4492021
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized …
JY Pierga, FC Bidard, C Mathiot, E Brain, S Delaloge, S Giachetti, ...
Clinical Cancer Research 14 (21), 7004-7010, 2008
4472008
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial
C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ...
Journal of Clinical Oncology 38 (27), 3138, 2020
4412020
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
E Vacchelli, Y Ma, EE Baracco, A Sistigu, DP Enot, F Pietrocola, H Yang, ...
Science 350 (6263), 972-978, 2015
4292015
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally …
D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ...
Annals of Oncology 32 (8), 994-1004, 2021
4192021
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer
F Cardoso, S Loibl, O Pagani, A Graziottin, P Panizza, L Martincich, ...
European journal of cancer 48 (18), 3355-3377, 2012
3802012
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
F Andre, B Job, P Dessen, A Tordai, S Michiels, C Liedtke, C Richon, ...
Clinical cancer research 15 (2), 441-451, 2009
3672009
Dual-energy contrast-enhanced digital mammography: initial clinical results
C Dromain, F Thibault, S Muller, F Rimareix, S Delaloge, A Tardivon, ...
European radiology 21, 565-574, 2011
3592011
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
R Rouzier, L Pusztai, S Delaloge, AM Gonzalez-Angulo, F Andre, ...
Journal of Clinical Oncology 23 (33), 8331-8339, 2005
3252005
The system can't perform the operation now. Try again later.
Articles 1–20